|
Gene: ALS2CL |
Gene summary for ALS2CL |
Gene summary. |
Gene information | Species | Human | Gene symbol | ALS2CL | Gene ID | 259173 |
Gene name | ALS2 C-terminal like | |
Gene Alias | RN49018 | |
Cytomap | 3p21.31 | |
Gene Type | protein-coding | GO ID | GO:0006996 | UniProtAcc | A0A024R2U1 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
259173 | ALS2CL | HCC1_Meng | Human | Liver | HCC | 2.23e-03 | -6.64e-03 | 0.0246 |
259173 | ALS2CL | HCC2_Meng | Human | Liver | HCC | 1.38e-08 | 7.06e-02 | 0.0107 |
259173 | ALS2CL | HCC2 | Human | Liver | HCC | 2.74e-08 | 2.52e+00 | 0.5341 |
259173 | ALS2CL | S027 | Human | Liver | HCC | 1.31e-09 | 5.67e-01 | 0.2446 |
259173 | ALS2CL | S028 | Human | Liver | HCC | 3.22e-17 | 5.30e-01 | 0.2503 |
259173 | ALS2CL | S029 | Human | Liver | HCC | 1.83e-12 | 6.08e-01 | 0.2581 |
259173 | ALS2CL | C04 | Human | Oral cavity | OSCC | 2.50e-03 | 2.76e-01 | 0.2633 |
259173 | ALS2CL | C21 | Human | Oral cavity | OSCC | 3.06e-06 | 2.58e-01 | 0.2678 |
259173 | ALS2CL | C30 | Human | Oral cavity | OSCC | 1.28e-12 | 7.11e-01 | 0.3055 |
259173 | ALS2CL | C51 | Human | Oral cavity | OSCC | 2.58e-09 | 3.66e-01 | 0.2674 |
259173 | ALS2CL | C57 | Human | Oral cavity | OSCC | 8.11e-04 | 2.42e-01 | 0.1679 |
259173 | ALS2CL | C06 | Human | Oral cavity | OSCC | 3.71e-02 | 5.79e-01 | 0.2699 |
259173 | ALS2CL | SYSMH1 | Human | Oral cavity | OSCC | 9.73e-03 | 7.82e-02 | 0.1127 |
259173 | ALS2CL | SYSMH2 | Human | Oral cavity | OSCC | 1.32e-07 | 2.16e-01 | 0.2326 |
259173 | ALS2CL | SYSMH3 | Human | Oral cavity | OSCC | 9.89e-10 | 3.14e-01 | 0.2442 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001605021 | Liver | HCC | vesicle organization | 194/7958 | 300/18723 | 5.58e-15 | 3.97e-13 | 194 |
GO:000703211 | Liver | HCC | endosome organization | 61/7958 | 82/18723 | 4.36e-09 | 1.15e-07 | 61 |
GO:00160508 | Oral cavity | OSCC | vesicle organization | 189/7305 | 300/18723 | 2.40e-17 | 2.14e-15 | 189 |
GO:00070327 | Oral cavity | OSCC | endosome organization | 59/7305 | 82/18723 | 1.41e-09 | 3.39e-08 | 59 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ALS2CL | SNV | Missense_Mutation | rs554056115 | c.2213G>A | p.Arg738His | p.R738H | Q60I27 | protein_coding | tolerated(0.14) | benign(0.01) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ALS2CL | SNV | Missense_Mutation | rs139526721 | c.565N>A | p.Ala189Thr | p.A189T | Q60I27 | protein_coding | tolerated(0.12) | benign(0.009) | TCGA-AX-A2HG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ALS2CL | SNV | Missense_Mutation | rs140756490 | c.1480N>A | p.Gly494Ser | p.G494S | Q60I27 | protein_coding | deleterious(0.02) | probably_damaging(1) | TCGA-AX-A3FT-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ALS2CL | SNV | Missense_Mutation | c.969G>T | p.Lys323Asn | p.K323N | Q60I27 | protein_coding | tolerated(0.1) | benign(0.033) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ALS2CL | SNV | Missense_Mutation | rs747127198 | c.775G>A | p.Val259Ile | p.V259I | Q60I27 | protein_coding | tolerated(0.07) | benign(0.028) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ALS2CL | SNV | Missense_Mutation | novel | c.2503N>A | p.Leu835Met | p.L835M | Q60I27 | protein_coding | deleterious(0.04) | probably_damaging(0.99) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ALS2CL | SNV | Missense_Mutation | c.2606C>T | p.Ser869Leu | p.S869L | Q60I27 | protein_coding | tolerated(0.24) | probably_damaging(0.998) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD | |
ALS2CL | SNV | Missense_Mutation | novel | c.40G>A | p.Glu14Lys | p.E14K | Q60I27 | protein_coding | tolerated(0.05) | probably_damaging(0.985) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
ALS2CL | SNV | Missense_Mutation | novel | c.1525N>G | p.Thr509Ala | p.T509A | Q60I27 | protein_coding | tolerated(0.38) | benign(0.119) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ALS2CL | SNV | Missense_Mutation | c.2668N>A | p.Val890Met | p.V890M | Q60I27 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D1-A15X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |